Evaluation of the acceptability of point of care diagnostic test for prenatal toxoplasmosis (translational research phase III).

Autor:	Londoño-Martinez JC; Grupo Parasitología Molecular (GEPAMOL), Centro de Investigaciones Biomédicas, Facultad de Ciencias de la Salud, Universidad del Quindio, Armenia, Colombia., Velasco-Velasquez S; Grupo Parasitología Molecular (GEPAMOL), Centro de Investigaciones Biomédicas, Facultad de Ciencias de la Salud, Universidad del Quindio, Armenia, Colombia., Cordero-Lopez S; Grupo Parasitología Molecular (GEPAMOL), Centro de Investigaciones Biomédicas, Facultad de Ciencias de la Salud, Universidad del Quindio, Armenia, Colombia., Osorio MF; Virrey Solís IPS, Armenia, Quindio, Colombia., Celis-Giraldo D; Grupo Parasitología Molecular (GEPAMOL), Centro de Investigaciones Biomédicas, Facultad de Ciencias de la Salud, Universidad del Quindio, Armenia, Colombia., Thibodeau J; The College, The University of Chicago, Chicago, IL, USA; Center for Global Health, University of Chicago, Chicago, IL, USA., Baird I; The College, The University of Chicago, Chicago, IL, USA; Center for Global Health, University of Chicago, Chicago, IL, USA., McLeod R; Department of Pediatrics (Infectious Diseases Division, University of Chicago, Chicago, IL, USA; CHESSU, Committee on Immunology, University of Chicago, Chicago, IL, USA; Chicago Medicine University of Chicago, Chicago, IL, USA., Gomez-Marin J; Grupo Parasitología Molecular (GEPAMOL), Centro de Investigaciones Biomédicas, Facultad de Ciencias de la Salud, Universidad del Quindio, Armenia, Colombia. Electronic address: gepamol2@uniquindio.edu.co.
Jazyk:	angličtina
Zdroj:	Journal of infection and public health [J Infect Public Health] 2023 Jan; Vol. 16 (1), pp. 15-24. Date of Electronic Publication: 2022 Nov 23.
DOI:	10.1016/j.jiph.2022.11.023
Abstrakt:	Background: A new point of care test (POC) was developed that is promising as a tool to enhance impact of prenatal care programs for toxoplasmosis, however, no reports exist about its use or acceptability for healthcare personnel and mothers in Colombia. Methods: This was a translational research - phase III study of the acceptability of a new POC test (Toxoplasma ICT IgG-IgM, LDBio) for qualitative diagnosis of toxoplasmosis in 783 pregnant women and 30 health personnel in primary health care sites in the city of Armenia, Quindío (Colombia). Along with collection of the results of diagnostic POC and confirmatory test and demographic information, we evaluated acceptability through measure of the willingness, credibility, and satisfaction by using questionnaires with a Likert scale during routine prenatal care visits. Results: POC positivity was 46.5% among pregnant participants and was significantly related to socioeconomic factors, including education level (p = 0.00000000) and insurance status (p = 0.00000015). A total of 93-97% of healthcare personnel indicated agreement to positive statements regarding total satisfaction and total credibility of the LDBio test, but qualitative questions identified "Difficulty in the test procedure" as the most common response about barriers to apply the test. Greater than 90% of pregnant participants agree that POC test should be routine for all pregnant woman and permanently implemented. Conclusions: The test had near complete acceptability. In future studies it is necessary to examine the effect of non-differentiation between IgG and IgM isotypes. Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Reagents were donated by LDBio (France). The donors do not participate in writing of the paper. Rima McLeod has participated in a patent application in the US to ensure the continued high quality of the ICT. (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu